Two New Antiseizure Drugs: A Pharmacist Perspective

Published Online: Tuesday, March 20, 2012
Follow Pharmacy_Times:
In this podcast, part of Epilepsy.com’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of Epilepsy.com, interviews Barry Gidal, PharmD, professor of pharmacy and neurology at the University of Wisconsin, about two new antiepileptic drugs (AEDs): ezogabine and perampanel.
 
Dr. Gidal explains that ezogabine, which was approved by the FDA in June 2011, helps to reduce seizure activity by keeping the potassium channels of neurons open, while perampanel, which has not yet been approved, blocks the stimulation of 1 of 3 key neuronal receptors that are thought to be key in starting and continuing seizures. He explains that both medications have shown very good promise in reducing seizure activity in patients who have failed to respond to multiple other AEDs and do not appear to have serious side effects or drug interaction problems.
 
To listen to the podcast, click here and scroll down to the October 28, 2011, episode.
Related Articles
The FDA today expanded the indication for perampanel hydrate (Fycompa) as an adjunctive treatment of primary generalized tonic-clonic seizures for patients aged 12 years or older with epilepsy.
The FDA has determined the current labeling for the anti-seizure medication ezogabine (Potiga) adequately describes its risks of vision loss and skin discoloration.
Family planning is especially challenging for women with epilepsy.
Controlling seizures is critical for patients with epilepsy, but side effects of antiepileptic drugs are another tremendous concern.
Latest Issues
$auto_registration$